Sharmilan Thanendrarajan
Overview
Explore the profile of Sharmilan Thanendrarajan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1044
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mohan Lal B, Alzubi M, Alrawabdeh J, Shaughnessy Jr J, Zhan F, Siegel E, et al.
Blood Adv
. 2025 Feb;
PMID: 39938011
No abstract available.
2.
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Smith R, et al.
Blood Adv
. 2025 Jan;
9(4):950-953.
PMID: 39786380
No abstract available.
3.
Cheng Y, Sun F, Alapat D, Wanchai V, Mery D, Siegel E, et al.
Blood Cancer J
. 2024 Nov;
14(1):194.
PMID: 39505839
Tumor immune microenvironmental alterations occur early in multiple myeloma (MM) development. In this study, we aim to systematically characterize the tumor immune microenvironment (TME) and the tumor-immune interactions from precursor...
4.
Patel T, Bachu R, Shrivastava T, Alrawabdeh J, Alzubi M, Hastings J, et al.
Clin Hematol Int
. 2024 Sep;
6(3):54-60.
PMID: 39345654
In our study of 246 newly diagnosed individuals with MGUS or SMM (115 MGUS, 131 SMM), we found that 19% reported anxiety, with no significant difference between the MGUS and...
5.
Akhtar O, Szabo A, Bhatlapenumarthi V, Forsberg M, Balev M, Patwari A, et al.
Br J Haematol
. 2024 Aug;
205(5):1830-1834.
PMID: 39192546
The Glasgow prognostic score (GPS) and CAR-HEMATOTOX (CAR-HT) score identify multiple myeloma (MM) patients at high risk for immune-mediated toxicity and early mortality with cellular immunotherapy. However, their association with...
6.
Naqvi S, Shrestha A, Alzubi M, Alrawabdeh J, Thanendrarajan S, Zangari M, et al.
EJHaem
. 2024 Aug;
5(4):789-792.
PMID: 39157593
Talquetamab is an approved therapy for relapsed multiple myeloma. This study examined dysgeusia and weight loss occurrences, alongside investigating symptom reversibility post-treatment cessation. Dysgeusia was prevalent, persisting in 15% of...
7.
Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Tricot G, et al.
Am J Hematol
. 2024 Aug;
99(11):2222-2224.
PMID: 39109821
No abstract available.
8.
Shrestha A, Alzubi M, Alrawabdeh J, Schinke C, Thanendrarajan S, Zangari M, et al.
EJHaem
. 2024 Jun;
5(3):554-559.
PMID: 38895072
Talquetamab recently received approval for relapsed refractory multiple myeloma. However, there is currently no available data on how patients perform with BCMA based agents after progression on talquetamab. Herein, we...
9.
Guo W, Strouse C, Mery D, Siegel E, Munshi M, Ashby T, et al.
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539451
Autologous stem cell transplantation (ASCT) has been a mainstay in myeloma treatment for over three decades, but patient prognosis post-ASCT varies significantly. In a retrospective study of 5259 patients with...
10.
Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, et al.
Blood Cancer J
. 2024 Mar;
14(1):35.
PMID: 38443345
The objective of our study was to report real-world data on the safety and efficacy of standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM). This is a multi-institutional retrospective...